BIOMAT Database Logo BIOMAT Database Logo

Inhaled nitric oxide for postoperative pulmonary hypertension in patients with congenital heart defects. 1992

A Haydar, and T Malhere, and P Mauriat, and D Journois, and P Pouard, and N Denis, and D Lefèbvre, and D Safran, and P Vouhé

UI MeSH Term Description Entries
D006976 Hypertension, Pulmonary Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES. Pulmonary Hypertension
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D009569 Nitric Oxide A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP. Endogenous Nitrate Vasodilator,Mononitrogen Monoxide,Nitric Oxide, Endothelium-Derived,Nitrogen Monoxide,Endothelium-Derived Nitric Oxide,Monoxide, Mononitrogen,Monoxide, Nitrogen,Nitrate Vasodilator, Endogenous,Nitric Oxide, Endothelium Derived,Oxide, Nitric,Vasodilator, Endogenous Nitrate
D011183 Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery. Complication, Postoperative,Complications, Postoperative,Postoperative Complication
D006330 Heart Defects, Congenital Developmental abnormalities involving structures of the heart. These defects are present at birth but may be discovered later in life. Congenital Heart Disease,Heart Abnormalities,Abnormality, Heart,Congenital Heart Defect,Congenital Heart Defects,Defects, Congenital Heart,Heart Defect, Congenital,Heart, Malformation Of,Congenital Heart Diseases,Defect, Congenital Heart,Disease, Congenital Heart,Heart Abnormality,Heart Disease, Congenital,Malformation Of Heart,Malformation Of Hearts
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000280 Administration, Inhalation The administration of drugs by the respiratory route. It includes insufflation into the respiratory tract. Drug Administration, Inhalation,Drug Administration, Respiratory,Drug Aerosol Therapy,Inhalation Drug Administration,Inhalation of Drugs,Respiratory Drug Administration,Aerosol Drug Therapy,Aerosol Therapy, Drug,Drug Therapy, Aerosol,Inhalation Administration,Administration, Inhalation Drug,Administration, Respiratory Drug,Therapy, Aerosol Drug,Therapy, Drug Aerosol

Related Publications

A Haydar, and T Malhere, and P Mauriat, and D Journois, and P Pouard, and N Denis, and D Lefèbvre, and D Safran, and P Vouhé
Inhaled nitric oxide as therapy for pulmonary hypertension in postoperative cases of congenital heart defects.
January 1996, Indian heart journal,
A Haydar, and T Malhere, and P Mauriat, and D Journois, and P Pouard, and N Denis, and D Lefèbvre, and D Safran, and P Vouhé
Inhaled low-dose nitric oxide for postoperative care in patients with congenital heart defects.
January 1997, Artificial organs,
A Haydar, and T Malhere, and P Mauriat, and D Journois, and P Pouard, and N Denis, and D Lefèbvre, and D Safran, and P Vouhé
Inhaled nitric oxide as a therapy for pulmonary hypertension after operations for congenital heart defects.
April 1994, The Journal of thoracic and cardiovascular surgery,
A Haydar, and T Malhere, and P Mauriat, and D Journois, and P Pouard, and N Denis, and D Lefèbvre, and D Safran, and P Vouhé
Inhaled nitric oxide for children with congenital heart disease and pulmonary hypertension.
December 1995, The Annals of thoracic surgery,
A Haydar, and T Malhere, and P Mauriat, and D Journois, and P Pouard, and N Denis, and D Lefèbvre, and D Safran, and P Vouhé
Nitric oxide-related compounds in patients with congenital heart defects and pulmonary hypertension.
June 2000, Pediatrics international : official journal of the Japan Pediatric Society,
A Haydar, and T Malhere, and P Mauriat, and D Journois, and P Pouard, and N Denis, and D Lefèbvre, and D Safran, and P Vouhé
Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart disease.
April 1998, The Journal of thoracic and cardiovascular surgery,
A Haydar, and T Malhere, and P Mauriat, and D Journois, and P Pouard, and N Denis, and D Lefèbvre, and D Safran, and P Vouhé
Inhaled nitric oxide for the postoperative management of pulmonary hypertension in infants and children with congenital heart disease.
March 2006, Anesthesia and analgesia,
A Haydar, and T Malhere, and P Mauriat, and D Journois, and P Pouard, and N Denis, and D Lefèbvre, and D Safran, and P Vouhé
Inhaled nitric oxide for the postoperative management of pulmonary hypertension in infants and children with congenital heart disease.
October 2005, The Cochrane database of systematic reviews,
A Haydar, and T Malhere, and P Mauriat, and D Journois, and P Pouard, and N Denis, and D Lefèbvre, and D Safran, and P Vouhé
Inhaled nitric oxide for the postoperative management of pulmonary hypertension in infants and children with congenital heart disease.
July 2014, The Cochrane database of systematic reviews,
A Haydar, and T Malhere, and P Mauriat, and D Journois, and P Pouard, and N Denis, and D Lefèbvre, and D Safran, and P Vouhé
Effects of inhaled nitric oxide on postoperative pulmonary circulation in patients with congenital heart disease.
January 1997, Artificial organs,
Copied contents to your clipboard!